Merck UK Expansion Cancelled – No State Investment
Here’s a summary of the key points from the provided text:
MSD is reducing its UK presence: The pharmaceutical company MSD is ending operations at its UK manufacturing site by the end of the year, resulting in 125 job losses.
Reasons cited: Lack of UK investment & undervaluation of medicines: MSD blames a lack of investment in the UK life science industry and the undervaluation of innovative medicines and vaccines by the UK government.
Broader Industry Trend: This isn’t an isolated incident. AstraZeneca also pulled a £450m investment earlier this year, and other companies are signaling similar concerns. Novartis has already been unable to launch several medicines in the UK.
NHS Spending on Pharmaceuticals is Down: Experts point to a decline in the percentage of healthcare spending allocated to pharmaceuticals in the UK (down from 15% to 9% over 10 years), compared to the OECD average of 14-20%. Companies need to be able to sell their products.
UK Competitiveness is Key: Industry leaders emphasize the UK’s declining competitiveness as the primary driver of these decisions. They highlight systematic under-investment in innovative products.
Not Just About Drug Pricing (Though it’s a factor): While drug pricing negotiations are ongoing,sources suggest the issue is broader than just price – it’s about the overall investment climate. The current pricing regime was agreed to less than 18 months ago.
Positive Area - Kings Cross Hub: The UK has* been attracting funding in the area of life sciences and AI around Kings Cross, but this isn’t enough to offset the broader issues.
In essence, the article paints a picture of a pharmaceutical industry losing confidence in the UK as a viable place to invest and operate, due to a combination of government policy, NHS spending priorities, and overall market competitiveness.